Forgot your password?

Forgot your username?

database > company
Rib-X Pharmaceuticals
Biotech Specialty Pharma
300 George Street Suite 301
New Haven, CT 06511-6663
phone:203.624.5606
fax:203.624.5627
Symbol Private
Founded 0
Employees
www.rib-x.com
Research Sector Biotech Specialty Pharma
Summary Description
New antibiotics for Serious Drug Resistant Infections
Management
Mark Leuchtenberger, President and Chief Executive Officer; Robert Conerly, Chief Financial Officer; Scott Hopkins, M.D.Chief Medical Officer; Anthony Sabatelli, Ph.D., J.D. Chief Patent Counsel Authorized House Counsel Eric Burak, Ph.D. Vice President, Advanced Preclinical Development Erin Duffy, Ph.D. Vice President, Discovery Research Jarrod Longcor Senior Director, Business Development
Keywords
antibiotics, infection,Oxazolidinones, Tetracyclines, Macrolides, X-ray crystallography, Delafloxacin, Skin Structure Infections, Radezolid, RX-04

Comment | Printable Version | Modify profile |
Updated: Jul. 08, 2011

Description
Rib-X Pharmaceuticals is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company's Nobel Prize winning platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development.
Products / Services
delafloxacin, radezolid, RX-02, and RX-04
Technology / Differentiation
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Strategy
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
Funding
Rib-X Pharmaceuticals, Inc. owns full commercialization rights to all of its product development and discovery programs. As these programs mature during the next few years, we will look to identify strategic partnerships for some of our programs. These collaborations will provide funding to advance our internal antibiotic drug discovery and clinical development programs and accelerate our growth into a commercial organization. Rib-X has the ability to enter into a wide variety of partnership agreements focused on our antibiotic research & discovery capabilities, development of existing compounds, and commercialization of our late stage clinical programs.
Status
In 2006, worldwide sales of all anti-infective drugs totaled approximately $66.5 billion, with sales of antibiotics accounting for approximately 50% of the total. The overall market is expected to continue its growth and the antibiotic market is expected to reach $45 billion by 2012. This growth is due in large part to the increasing emergence of multi-drug resistant bacterial strains, the deficiencies of currently available antibiotics to treat certain serious bacterial infections and a vulnerable aging population throughout the world's major markets. The costs associated with managing antibiotic resistance in the U.S. have reached an estimated $10 billion per year and continue to escalate.